DRREDDY

Fundamental View-

Dr. Reddy’s Laboratories Ltd. is one of India’s leading pharmaceutical companies, with a robust global footprint spanning North America, Europe, India, Russia, and emerging markets. The company operates across multiple segments including generics, active pharmaceutical ingredients (APIs), proprietary products, biosimilars, and over-the-counter (OTC) offerings. Financially, Dr. Reddy’s has shown consistent performance with strong revenue growth, driven primarily by its U.S. generics business and expansion into key international markets. For FY24, the company reported improved EBITDA margins, strong free cash flow, and minimal debt on its balance sheet, reflecting healthy financial discipline. Its R&D spending remains high, around 8–9% of revenue, indicating a focus on pipeline development, complex generics, and innovation. Strategic acquisitions, portfolio diversification, regulatory compliance, and supply chain efficiency have further strengthened its position in the global pharma space. Based on the daily chart of Dr. Reddy’s Laboratories, the stock has shown a corrective phase after a strong rally in June, and it's currently consolidating around the 1250–1260 zone. The price is trading near its 55-day EMA and 50-day SMA, indicating a critical support area. The RSI stands at 42.63, suggesting the stock is in neutral to slightly oversold territory. MACD remains in bearish territory with no clear crossover yet, reflecting weak momentum. Parabolic SAR dots are currently above the price, indicating a short-term downtrend. However, with Q1 FY26 results scheduled for 23rd July, the stock may see heightened volatility and a potential reversal if earnings surprise positively. The 1230–1240 zone acts as an important support, while on the upside, a break above 1280–1300 may trigger a fresh rally toward 1340–1360. Any dip around support could be a low-risk buying opportunity ahead of the earnings announcement.